GSK and ViiV score breakthrough therapy designation in HIV prevention, as Truvada showdown draws nearer

A little less than a week after beefing up the data package it plans to take to the FDA for the experimental HIV drug cabotegravir, GSK-owned ViiV Healthcare has received good news on the medicine’s prospects.